These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

527 related items for PubMed ID: 25270521

  • 1. Safety of antiandrogen therapy for treating prostate cancer.
    Ricci F, Buzzatti G, Rubagotti A, Boccardo F.
    Expert Opin Drug Saf; 2014 Nov; 13(11):1483-99. PubMed ID: 25270521
    [Abstract] [Full Text] [Related]

  • 2. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    Cochrane Database Syst Rev; 2014 Jun 30; 2014(6):CD009266. PubMed ID: 24979481
    [Abstract] [Full Text] [Related]

  • 3. Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer.
    Blackledge G, Kolvenbag G, Nash A.
    Anticancer Drugs; 1996 Jan 30; 7(1):27-34. PubMed ID: 8742095
    [Abstract] [Full Text] [Related]

  • 4. Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
    Gillatt D.
    J Cancer Res Clin Oncol; 2006 Aug 30; 132 Suppl 1():S17-26. PubMed ID: 16845534
    [Abstract] [Full Text] [Related]

  • 5. Current topics and perspectives relating to hormone therapy for prostate cancer.
    Suzuki H, Kamiya N, Imamoto T, Kawamura K, Yano M, Takano M, Utsumi T, Naya Y, Ichikawa T.
    Int J Clin Oncol; 2008 Oct 30; 13(5):401-10. PubMed ID: 18946750
    [Abstract] [Full Text] [Related]

  • 6. Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer: a Cochrane systematic review.
    Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, Wullich B, Meerpohl JJ.
    BJU Int; 2015 Jul 30; 116(1):30-6. PubMed ID: 25523493
    [Abstract] [Full Text] [Related]

  • 7. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.
    Crawford ED, Schellhammer PF, McLeod DG, Moul JW, Higano CS, Shore N, Denis L, Iversen P, Eisenberger MA, Labrie F.
    J Urol; 2018 Nov 30; 200(5):956-966. PubMed ID: 29730201
    [Abstract] [Full Text] [Related]

  • 8. Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    Migliari R, Muscas G, Murru M, Verdacchi T, De Benedetto G, De Angelis M.
    Arch Ital Urol Androl; 1999 Dec 30; 71(5):293-302. PubMed ID: 10673793
    [Abstract] [Full Text] [Related]

  • 9. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
    Prescrire Int; 2013 Feb 30; 22(135):48-51. PubMed ID: 23444510
    [Abstract] [Full Text] [Related]

  • 10. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T, Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.
    J Urol; 2008 Sep 30; 180(3):921-7. PubMed ID: 18635218
    [Abstract] [Full Text] [Related]

  • 11. Effect of delayed maximal androgen blockade therapy for patients with advanced prostate cancer who fail to respond to initial androgen deprivation monotherapy.
    Takayanagi A, Masumori N, Hashimoto J, Kyoda Y, Yanase M, Tsukamoto T.
    Jpn J Clin Oncol; 2010 Dec 30; 40(12):1154-8. PubMed ID: 20647233
    [Abstract] [Full Text] [Related]

  • 12. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
    Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.
    Jpn J Clin Oncol; 2012 Jun 30; 42(6):534-40. PubMed ID: 22438406
    [Abstract] [Full Text] [Related]

  • 13. Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer.
    Hashimoto K, Masumori N, Hashimoto J, Takayanagi A, Fukuta F, Tsukamoto T.
    Jpn J Clin Oncol; 2011 Mar 30; 41(3):405-10. PubMed ID: 20947624
    [Abstract] [Full Text] [Related]

  • 14. Maximal androgen blockade for advanced prostate cancer.
    Klotz L.
    Best Pract Res Clin Endocrinol Metab; 2008 Apr 30; 22(2):331-40. PubMed ID: 18471790
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T, Fujii Y, Yokoyama M, Ishioka J, Matsuoka Y, Numao N, Saito K, Koga F, Masuda H, Kawakami S, Kihara K.
    BJU Int; 2012 Oct 30; 110(8):1149-55. PubMed ID: 22369348
    [Abstract] [Full Text] [Related]

  • 16. Antiandrogens in the treatment of prostate cancer.
    Wirth MP, Hakenberg OW, Froehner M.
    Eur Urol; 2007 Feb 30; 51(2):306-13; discussion 314. PubMed ID: 17007995
    [Abstract] [Full Text] [Related]

  • 17. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May 30; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 18. Combination hormonal therapy: a reassessment within advanced prostate cancer.
    Moul JW, Chodak G.
    Prostate Cancer Prostatic Dis; 2004 Sep 30; 7 Suppl 1():S2-7. PubMed ID: 15365575
    [Abstract] [Full Text] [Related]

  • 19. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
    Guo C, Yeh S, Niu Y, Li G, Zheng J, Li L, Chang C.
    Cancer Lett; 2017 Jul 01; 397():133-143. PubMed ID: 28323036
    [Abstract] [Full Text] [Related]

  • 20. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
    Beckmann K, Garmo H, Adolfsson J, Bosco C, Johansson E, Robinson D, Holmberg L, Stattin P, Van Hemelrijck M.
    Eur Urol; 2019 Apr 01; 75(4):676-683. PubMed ID: 30497883
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.